Biosimilar Interchangeability Does Not Equate To Substitution Under House Legislation
This article was originally published in The Pink Sheet Daily
Executive Summary
Bills from Rep. Waxman and Rep. Eshoo differ in their approaches, but both leave a lot of work to the states.
You may also be interested in...
Biosimilars: How Many Votes Is A Chairmanship Worth?
Eshoo introduces her biosimilars bill with 43 co-sponsors, but Waxman controls the agenda.
Biosimilars: How Many Votes Is A Chairmanship Worth?
Eshoo introduces her biosimilars bill with 43 co-sponsors, but Waxman controls the agenda.
Medicare Coverage For FOBs: MedPAC Weighs Least Costly Alternative, Coding Options
The Medicare Payment Advisory Commission is taking up payment issues for follow-on biologics as legislation establishing a regulatory pathway for approving such products gathers momentum in Congress.